Evidence map›Paper›PMID 42112081›Full record

ArticleImmunotherapy advances2025

Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8

Gerwin G W Sandker, René Raavé, Inês F Antunes, Milou Boswinkel, Lenneke A M Cornelissen, Gerben M Franssen, Janneke Molkenboer-Kuenen, Peter J Wierstra, Iris M Hagemans, Erik F J de Vries and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gerwin G W SandkerDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-0997-5440
René RaavéDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0001-6066-4448
Inês F AntunesDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-8003-5291
Milou BoswinkelDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
Lenneke A M CornelissenDepartment of Radiation Oncology, Radiotherapy & OncoImmunology Lab, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0003-2210-1606
Gerben M FranssenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
Janneke Molkenboer-KuenenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0009-0007-0879-5660
Peter J WierstraDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0003-4388-9818
Iris M HagemansDepartment of Tumor Immunology and the Institute for Chemical Immunology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0003-3197-648X
Erik F J de VriesDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-6915-1590
Johan BussinkDepartment of Radiation Oncology, Radiotherapy & OncoImmunology Lab, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-5751-4796
Gosse J AdemaDepartment of Radiation Oncology, Radiotherapy & OncoImmunology Lab, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-6750-1665
Martijn VerdoesDepartment of Tumor Immunology and the Institute for Chemical Immunology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0001-8753-3528
Erik H J G AarntzenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-3809-0182
Sandra HeskampDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0001-7250-0846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Many immunotherapies focus on (re)invigorating CD8 Methods: B16F10/OVA tumor-bearing C57BL/6 mice ( Results: All approaches showed uptake in CD8-rich tissues, with preferential spleen targeting. Biodistribution analyses showed tumor uptake exceeded blood level for [ Conclusion: [

Indexed as

anti-CD8 antibodyCD8-positive T-lymphocytesex vivo labeled CD8+ T cellsinterleukin-2PET/CT

Identifiers

PMID42112081
PMCPMC13151886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.